Manulife announces intention to launch Normal Course Issuer Bid

Core Viewpoint - Manulife Financial Corporation intends to launch a Normal Course Issuer Bid (NCIB) to purchase up to 42 million common shares, approximately 2.5% of its outstanding shares, as part of its capital management strategy to enhance shareholder value [1]. Group 1: NCIB Details - The NCIB is subject to approval from the Toronto Stock Exchange (TSX) and has already received approval from the Office of the Superintendent of Financial Institutions (Canada) [1]. - As of January 31, 2026, Manulife had 1,676,743,043 common shares issued and outstanding [1]. - The bid period will commence after TSX acceptance and will last for up to one year, with all shares acquired under the NCIB to be cancelled [1]. Group 2: Purchase Mechanisms - Purchases may occur through TSX, New York Stock Exchange, and alternative trading systems at market prices or other permitted prices [1]. - Manulife may also acquire shares outside Canada and the U.S. and enter into derivative-based programs to support its purchase activities, subject to regulatory approval [1]. - The total number of shares purchased under the NCIB and other arrangements will not exceed 42 million [1]. Group 3: Previous NCIB Performance - Manulife's previous NCIB (2025 NCIB) commenced on February 24, 2025, allowing for the purchase of up to 51.5 million common shares, which was completed by January 22, 2026, at an average purchase price of $44.28 per share [1].